Aroa BiosurgeryAROAF +35.24%39 EBIT per Share is $0.01 as of Mar. 2026. GuruFocus rates AROAF with a GF Score™ of 39/100 and a GF Value™ of $0.71 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 691 Medical Devices & Instruments companies, Aroa Biosurgery ranks better than 91.17% on this metric.
Aroa Biosurgery's EBIT per Share for the
six
months ended in Mar. 2026 was $0.01.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.01.
During the past 3 years, the average EBIT per Share Growth Rate was 56.30% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 36.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Aroa Biosurgery's EBIT per Share or its related term are showing as below:
AROAF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 2.1 Med: 9.1 Max: 56.3
Current: 56.3
During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Aroa Biosurgery was 56.30% per year. The lowest was 2.10% per year. And the median was 9.10% per year.
AROAF's 3-Year EBIT Growth Rate is ranked better than 91.17% of 691
companies
in the Medical Devices & Instruments industry
Industry Median: 9.6
vs AROAF: 56.30
Aroa Biosurgery (OTCPK:AROAF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Aroa Biosurgery EBIT per Share Related Terms
Aroa Biosurgery EBIT per Share Historical Data
* Premium members only.
The historical data trend for Aroa Biosurgery's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aroa Biosurgery (AROAF) has a EBIT per Share of $0.01 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Aroa Biosurgery and its competitors. According to the industry distribution chart, Aroa Biosurgery ranks #61 out of 691 companies in the Medical Devices & Instruments industry, placing it in the top 8.8%.
Is Aroa Biosurgery's EBIT per Share too high?
Aroa Biosurgery's current EBIT per Share is $0.01. The Medical Devices & Instruments industry median EBIT per Share is 9.60. Aroa Biosurgery's value of $0.01 is 99.9% below this industry median. Based on the distribution chart, Aroa Biosurgery ranks #61 out of 691 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Aroa Biosurgery has a GF Score™ of 39/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aroa Biosurgery's EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Aroa Biosurgery ranks #61 out of 691 companies for EBIT per Share. This places Aroa Biosurgery in the top 9% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 9.60. Aroa Biosurgery's value of $0.01 is 99.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.60, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aroa Biosurgery's current EBIT per Share of $0.01 is 99.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Aroa Biosurgery and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aroa Biosurgery's current EBIT per Share is $0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aroa Biosurgery stock overvalued right now?
Based on GuruFocus' analysis, Aroa Biosurgery (AROAF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.71, compared to a current price of $0.52 — trading 26.8% below its estimated fair value. The current EBIT per Share is $0.01 and 99.9% below the Medical Devices & Instruments industry median of 9.60. Aroa Biosurgery's overall GF Score™ is 39/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Aroa Biosurgery (AROAF), the current EBIT per Share is $0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aroa Biosurgery (AROAF) Overvalued in 2026?
Based on GuruFocus' analysis, Aroa Biosurgery stock appears to be undervalued.
The current stock price of $0.52 is trading 26.8% below its estimated GF Value™ of $0.71.
GuruFocus considers Aroa Biosurgery to be Modestly Undervalued.
Key valuation signals for AROAF:
EBIT per Share: $0.01
GF Value™: $0.71 vs. price of $0.52 (26.8% below fair value)
Industry Position: 99.9% below the Medical Devices & Instruments median (#61 of 691)
No single metric tells the full story. See the AROAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
39GF Score
Get the complete analysis for AROAF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AROAF has been successfully added to your 
